Skip to main content
. Author manuscript; available in PMC: 2014 Mar 28.
Published in final edited form as: Cancer. 2013 Feb 13;119(10):1823–1831. doi: 10.1002/cncr.27986

TABLE 3.

Summary of Adverse Events, Regardless of Attribution

Adverse Event No. of Adverse Events (%)
Any Grade Grade 3 Grade 4
Hyperglycemia 15 (100) 5 (33) 1 (7)
Low hemoglobin 14 (93) 1 (7) 0 (0)
Thrombocytopenia 13 (87) 1 (7) 1 (7)
Fatigue 13 (87) 2 (13) 0 (0)
ALT elevation 12 (80) 0 (0) 0 (0)
Hypercholesterolemia 12 (80) 0 (0) 0 (0)
Hypertriglyceridemia 12 (80) 0 (0) 0 (0)
AST elevation 11 (73) 0 (0) 0 (0)
Leukopenia 10 (67) 6 (40) 1 (7)
Lymphopenia 10 (67) 6 (40) 4 (27)
Hypomagnesemia 10 (67) 0 (0) 0 (0)
Hypoalbuminemia 9 (60) 0 (0) 0v
Diarrhea 9 (60) 0 (0) 0 (0)
Nausea 9 (60) 0 (0) 0 (0)
Hyponatremia 9 (60) 1 (7) 0 (0)
Constipation 8 (53) 0 (0) 0 (0)
Creatinine elevation 8 (53) 0 (0) 0 (0)
Rash, acneiform 8 (53) 0 (0) 0 (0)
Alkaline phosphatase elevation 7 (47) 0 (0) 0v
Neutropenia 7 (47) 3 (20) 3 (20)
Hypokalemia 7 (47) 3 (20) 0 (0)
Dysgeusia 6 (40) 0 (0) 0 (0)
Febrile neutropenia 3 (20) 2 (13) 1 (7)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.